Razan Awan: Large Cohort Study Questions Routine Use of Dual Antiplatelet Therapy After TAVI
ٌRazan Awan, Deputy Director of Residency Training Program at King Fahd Armed Forces Hospital, Cardiology Clinical Pharmacy Specialist, shared a post on LinkedIn about a recent article she and her colleagues co-authored, published in Journal of Clinical Medicine, adding:
“Our new paper has just been published!
‘Single Versus Dual Antiplatelet Therapy After Transcatheter Aortic Valve Implantation in Patients Without Chronic Anticoagulation.’
Journal of Clinical Medicine — Published June 5, 2026
In this work, we analyzed 662 consecutive TAVI patients without chronic anticoagulation to compare single antiplatelet therapy (SAPT) versus dual antiplatelet therapy (DAPT).
Across multiple analytical models — including time-varying, intention-to-treat, landmark, and IPTW-weighted Cox analyses — no statistically significant difference was found between SAPT and DAPT in ischemic MACE (death, stroke, or MI) or net adverse clinical events.
These real-world findings support SAPT as a reasonable default antiplatelet strategy after TAVI, consistent with current ACC/AHA and ESC guidelines.
A special thank you to our lead author Monirah Albabtain, and corresponding author Amr Arafat, and to all co-authors for their incredible collaboration and dedication: Aisha Alrasheedi, Maha M. AlHarthi, Zaid Alanazi, and Nawaf Aldhubayti.”
Title: Single Versus Dual Antiplatelet Therapy After Transcatheter Aortic Valve Implantation in Patients Without Chronic Anticoagulation
Authors: Monirah A. Albabtain, Aisha Alrasheedi, Razan M. Awan, Maha Alharthi, Zaid Alanazi, Nawaf Aldhubayti, Amr A. Arafat
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 30, 2026, 17:43Santagata Davide: Can Targeting Inflammation Help Prevent Thrombosis?
-
Oct 30, 2026, 17:38Patrick Ellsworth: Supporting Patients and Families Through Bleeding Disorders Awareness and Community Initiatives
-
Oct 30, 2026, 17:33Ed Shovelin: Comparative Hemostatic Performance of CRP-A and Equine Fibrillar Collagen
-
Oct 30, 2026, 16:52Tosin Ola: A New Era in Sickle Cell Disease Treatment and the Question of Access
-
Oct 30, 2026, 16:48Cedric Hermans: The Next Generation of FVIIIa-Mimetic Antibodies in Haemophilia A
-
Oct 30, 2026, 16:44Shehab Mohamed: Recognizing Isolated Thrombocytopenia as a Presentation of MDS
-
Oct 30, 2026, 16:40Amrita Sarkar: Advancing the Diagnosis of Anti-PF4 Syndromes
-
Oct 30, 2026, 16:35James Garrard: Driving Innovation in Stroke Care Through Global Collaboration
-
Oct 30, 2026, 16:19Cesar de Almeida Neto: Hemo 2026 Roundtable Focuses on the Challenges of Patient Blood Management